A. Bay-Jensen

发表

The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?

C. Christiansen, S. Abramson, S. Goldring, 2013, Annals of the rheumatic diseases.

Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

L. Arendt-Nielsen, M. Hochberg, V. Kraus, 2022, Osteoarthritis and cartilage open.

The intestinal tissue homeostasis – the role of extracellular matrix remodeling in inflammatory bowel disease

J. Kjeldsen, M. Karsdal, J. Mortensen, 2019, Expert review of gastroenterology & hepatology.

A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)

P. Hägglund, P. Qvist, M. Koizumi, 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials

C. Christiansen, P. Qvist, K. Henriksen, 2011, Journal of clinical pharmacology.

Large scale meta-analysis of urinary C-terminal telopeptide, serum cartilage oligomeric protein and matrix metalloprotease degraded type II collagen and their role in prevalence, incidence and progression of osteoarthritis.

A. Hofman, A. Uitterlinden, T. Spector, 2014, Osteoarthritis and cartilage.

Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?

C. Christiansen, J. Jordan, S. Abramson, 2016, Scandinavian journal of rheumatology.

POS0966 IDENTIFICATION OF PATIENTS AFFECTED WITH ANKYLOSING SPONDYLITIS AND INFLAMMATORY BOWEL DISEASE OVERLAP USING COLLAGEN BIOMARKERS

M. Karsdal, K. Kuhn, A. Bay-Jensen, 2021 .

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis

J. Smolen, M. Kloppenburg, R. Ramonda, 2020, Scandinavian journal of rheumatology.

Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

M. Karsdal, C. Christiansen, E. Dam, 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation

M. Karsdal, C. Christiansen, B. Riis, 2010, BMC musculoskeletal disorders.

AB0192 Serum measures of type i collagen degradation are surrogate markers of joint destruction and progression; first steps towards a prognostic score

H. Nielsen, C. Bager, A. Bay-Jensen, 2017 .

Segregating OA patients with and without joint inflammation using two biomarkers of connective tissue inflammation

M. Karsdal, C. Christiansen, B. Riis, 2015 .

P204 Endotrophin (PRO-C6) is associated with MRE confirmed intestinal strictures and Protein FingerPrint biomarkers of collagen degradation is associated with ulcerations in paediatric Crohn’s disease patients – results from the ImageKids study

A. Griffiths, R. Baldassano, P. Church, 2022, Journal of Crohn's and Colitis.

P516 Serological biomarkers of tissue remodeling are associated with endoscopic remission in Crohn’s disease patients treated with GED-0301 (mongersen)

M. Karsdal, B. Feagan, G. Horan, 2021 .

SAT0504 Predictive ability of biomarkers linked with synovitis for future incidence of painful knee osteoarthritis in a community based cohort of middle-age women

T. Spector, N. Arden, D. Hart, 2017 .

IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific link between IL-37 and MMP-3.

P. M. van der Kraan, P. V. van Lent, F. van de Loo, 2019, Osteoarthritis and cartilage.

Reflections from the OARSI 2022 clinical trials symposium: The pain of OA-Deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design.

V. Kraus, C. Ladel, N. Nikolov, 2023, Osteoarthritis and cartilage.

Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover.

C. Christiansen, L. Arendt-Nielsen, H. C. Hoeck, 2014, Osteoarthritis and cartilage.

Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes.

M. Karsdal, K. Henriksen, D. Leeming, 2021, Clinical biochemistry.

Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?

M. Karsdal, K. Bohren, K. Henriksen, 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

A machine learning approach for the identification of new biomarkers for knee osteoarthritis development in overweight and obese women.

S. Bierma-Zeinstra, J. Bacardit, Y. Henrotin, 2017, Osteoarthritis and cartilage.

Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the Intensive Diet and Exercise for Arthritis trial (IDEA).

M. Karsdal, B. Nicklas, A. Guermazi, 2017, Osteoarthritis and cartilage.

Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development

M. Karsdal, M. Larsen, K. Henriksen, 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria.

M. Karsdal, A. Mobasheri, Y. Henrotin, 2016, Osteoarthritis and cartilage.

Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria.

M. Karsdal, L. Ranganath, A. Milan, 2015, JIMD reports.

Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?

C. Christiansen, J. Jordan, S. Abramson, 2016, Scandinavian journal of rheumatology.

Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix.

M. Karsdal, A. Gigout, C. Ladel, 2017, Osteoarthritis and cartilage.

The development and characterization of an ELISA specifically detecting the active form of cathepsin K.

M. Karsdal, W. Maksymowych, K. Henriksen, 2013, Clinical biochemistry.

Association between biochemical cartilage markers and clinical symptoms in patients with hip osteoarthritis: cohort study with 2-year follow-up.

M. Karsdal, S. Bierma-Zeinstra, R. Rozendaal, 2014, Osteoarthritis and cartilage.

Osteoarthritis year in review 2018: biomarkers (biochemical markers).

S. Bierma-Zeinstra, F. Saberi Hosnijeh, A. Bay-Jensen, 2019, Osteoarthritis and cartilage.